| Companies sponsors |
Novartis Gene Therapies (onasemnogene abeparvovec) |
| Others |
Department of Health and Social Care |
| |
European Alliance for Newborn Screening in Spinal Muscular Atrophy |
| |
NHS England |
| Patient carer groups |
Ally Cadence Trust for Spinal Muscular Atrophy |
| |
Arthritis and Musculoskeletal Alliance |
| |
Beacon |
| |
Brain and Spine Foundation |
| |
Brain Charity |
| |
Contact |
| |
Disability Rights UK |
| |
Genetic Alliance UK |
| |
Leonard Cheshire Disability |
| |
Muscular Dystrophy UK |
| |
National Children’s Bureau |
| |
Neurological Alliance |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Spinal Muscular Atrophy UK (SMA UK) |
| |
The Annabelle Rose Foundation for Spinal Muscular Atrophy |
| |
Together for Short Lives |
| |
TreatSMA |
| Professional groups |
Association of Anaesthetists |
| |
Association of British Neurologists |
| |
Association of Genetic Nurses and Counsellors |
| |
Association of Paediatric Anaesthetists of Great Britain and Ireland |
| |
Association of Surgeons of Great Britain and Ireland |
| |
British Dietetic Association |
| |
British Institute of Musculoskeletal Medicine |
| |
British Myology Society |
| |
British Neuropathological Society |
| |
British Orthopaedic Association |
| |
British Paediatric Neurology Association |
| |
British Society for Children's Orthopaedic Surgery |
| |
British Society for Gene and Cell Therapy |
| |
British Society for Genetic Medicine |
| |
British Society for Human Genetics |
| |
British Society of Rehabilitation Medicine |
| |
Chartered Society for Physiotherapy |
| |
Institute of Neurology |
| |
Neonatal & Paediatric Pharmacists Group |
| |
Primary Care and Community Neurology Society |
| |
Royal College of Anaesthetists |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Paediatrics & Child Health |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Surgeons |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
SMA Reach |
| |
Treat-NMD |
| |
UK Clinical Pharmacy Association |
| |
UK Genetic Testing Network |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
None |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
National Services Division |
| |
Neurological Alliance of Scotland |
| |
NHS Alliance |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Wales Neurological Alliance |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Cystic Fibrosis & Genetic Disorders Group |
| |
Cochrane Neuromuscular |
| |
Genomics England |
| |
John Walton Muscular Dystrophy Research Centre |
| |
MRC Centre for Neuromuscular Diseases |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |